Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

A novel form of amyloid deposited at the site of enfuvirtide injection.

Naujokas A, Vidal CI, Mercer SE, Harp J, Kurtin PJ, Fox LP, Thompson MM.

J Cutan Pathol. 2012 Feb;39(2):220-1; quiz 219. doi: 10.1111/j.1600-0560.2012.01865_2.x. No abstract available.

PMID:
22264247
2.

Localized amyloidosis at the site of enfuvirtide injection.

Morilla ME, Kocher J, Harmaty M.

Ann Intern Med. 2009 Oct 6;151(7):515-6. No abstract available.

PMID:
19805777
3.

[Enfuvirtide].

Gerstoft J.

Ugeskr Laeger. 2004 Nov 22;166(48):4355-7. Danish. No abstract available.

PMID:
15587625
4.

Enfuvirtide: patient acceptance and strategies for managing injection-site reactions.

Rice C, Wilantewicz H.

AIDS Read. 2006 Sep;16(9):470-4, 490-1.

PMID:
17024766
5.

Enfuvirtide: a new class of antiretroviral therapy for HIV infection.

Leao JC, Frezzini C, Porter S.

Oral Dis. 2004 Nov;10(6):327-9.

PMID:
15533206
6.

Enfuvirtide (Fuzeon).

[No authors listed]

Proj Inf Perspect. 2003 Oct;(36):4-5.

PMID:
14696566
7.

Relapse of intravenous drug use triggered by enfuvirtide, a parenteral antiretroviral medication.

Avelino-Silva VI, Li HY, Novaes CT.

AIDS Patient Care STDS. 2012 Feb;26(2):71-2. doi: 10.1089/apc.2011.0343. Epub 2011 Dec 9.

PMID:
22148866
8.

Fuzeon treatment forum, January 2004.

Burgess GE.

Surviv News (Atlanta Ga). 2004 Jan-Feb;15(1):10. No abstract available.

PMID:
15032144
9.

Safety and efficacy of enfuvirtide for 48 weeks as part of an optimized antiretroviral regimen in pediatric human immunodeficiency virus 1-infected patients.

Wiznia A, Church J, Emmanuel P, Eppes S, Rowell L, Evans C, Bertasso A; T20-310 Study Group.

Pediatr Infect Dis J. 2007 Sep;26(9):799-805.

PMID:
17721374
10.

New partnership calls for clinical testing of two fusion inhibitors.

Slovick J.

Posit Living. 1999 Aug;8(7):15, 62. No abstract available.

PMID:
12492078
11.

Interaction between enfuvirtide, an injectable fusion inhibitor, and niacin in an HIV-infected patient.

Oates E, Dzintars K.

Ann Pharmacother. 2010 Dec;44(12):2014-7. doi: 10.1345/aph.1P346. Epub 2010 Nov 2.

PMID:
21045170
12.

Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.

Belperio PS, Mole LA, Halloran J, Boothroyd DB, Thomas IC, Backus LI.

Ann Pharmacother. 2008 Nov;42(11):1573-80. doi: 10.1345/aph.1L265. Epub 2008 Oct 21.

PMID:
18940919
13.

Serious infection from Staphylococcus aureus in 2 HIV-infected patients receiving fusion inhibitor therapy.

Gaughan EM, Ritter ML, Kumar PN, Timpone JG.

AIDS Read. 2008 May;18(5):266-8.

PMID:
18589482
14.

Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.

Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arastéh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.

J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):413-21.

PMID:
16280695
15.

A prospective clinical and pathological examination of injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.

Myers SA, Selim AA, McDaniel MA, Hall R, Zhang Y, Bartlett JA, True AL.

Antivir Ther. 2006;11(7):935-9.

PMID:
17302257
16.

[Entry inhibitors. Ring-free for a new principle of action].

Rümmelein N, Jäger H.

MMW Fortschr Med. 2003 Apr 28;145 Spec No 1:16-20. German.

PMID:
15011578
17.

Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide.

Ball RA, Kinchelow T; ISR Substudy Group.

J Am Acad Dermatol. 2003 Nov;49(5):826-31.

PMID:
14576660
18.

Successful desensitization of enfuvirtide-induced skin hypersensitivity reaction.

Shahar E, Moar C, Pollack S.

AIDS. 2005 Mar 4;19(4):451-2. No abstract available.

PMID:
15750403
19.

Impact of education and support on the tolerability and quality of life in a cohort of HIV-1 infected patients treated with enfuvirtide (SURCOUF Study).

Allavena C, Prazuck T, Reliquet V, Verdon R, Perré P, Le Moal G, Billaud E, Raffi F.

J Int Assoc Physicians AIDS Care (Chic). 2008 Jul-Aug;7(4):187-92. doi: 10.1177/1545109708322015. Epub 2008 Jul 3.

PMID:
18599881
20.

Successful desensitization of enfuvirtide after a first attempt failure.

Machado ES, Passoni LF, Sidi LC, Andrade HB, De Menezes JA.

AIDS. 2006 Oct 24;20(16):2130-1. No abstract available.

PMID:
17053365

Supplemental Content

Support Center